Kite Pharma (KITE) to resume trading at 4:30PM ET
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Nasdaq outshines Wall St peers on tech boost, earnings glee
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Kite Pharma (KITE) Shares Pop Higher on Trading Resumption
September 26, 2016 4:32 PM EDTKite Pharma (NASDAQ: KITE) shares rise upon resumption. The stock was up as much as 16 percent this afternoon.
... MoreJuno Therapeutics (JUNO) Gains on Kite Pharma News
September 26, 2016 4:05 PM EDTJuno Therapeutics (NASDAQ: JUNO) gains after-hours following positive trial news from rival Kite Pharma, Inc., (Nasdaq: KITE). Shares are up 8.6%.
Kite... More
Kite Pharma (KITE) Announces Positive Topline Data from KTE-C19 ZUMA-1 Study in Aggressive NHL
September 26, 2016 4:02 PM EDTKite Pharma, Inc., (Nasdaq: KITE) announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p... More
Kite Pharma (KITE) trading halted with news pending
September 26, 2016 4:00 PM EDTKite Pharma (NASDAQ: KITE) trading halted with news pending.
... MoreKite Pharma (KITE): Reiterating Buy Ahead of ZUMA-1 Study - Stifel
September 22, 2016 7:15 AM EDTStifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) ahead of top-line data from the interim analysis of the ZUMA-1 study, due by the end of the month.
The analyst noted that conversations with clinicians... More
